Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 10, 2917, PolarityTE, Inc., a Delaware corporation (the “Company”), entered into new executive employment
agreements, effective as of November 10, 2017 (the “Effective Date”) with each of Dr. Denver Lough, Dr. Edward Swanson,
John Stetson and Cameron Hoyler, as further described below.
Dr.
Lough
On
November 10, 2017, the Company entered into a new executive employment agreement (the “Lough Agreement”) with Dr.
Lough, effective as of the Effective Date, providing for the continuation of his role as the Chief Executive Officer and Chief
Scientific Officer of the Company for a term of three years, which term shall be shall be automatically renewed for successive
one year periods thereafter unless either party provides the other party with written notice of his or its intention not to renew
the Lough Agreement at least three months prior to the expiration of the initial term.
Pursuant
to the Lough Agreement and in consideration for his services to the Company, Dr. Lough received a $150,000 continuation bonus
and will receive a base salary of $530,000 per annum in accordance with the Company’s regular payroll practices. For each
fiscal year during the term of employment, Dr. Lough shall be eligible to receive a bonus in the amount of 100% of annual salary,
if any, as may be determined from time to time by the Board in its discretion and shall be eligible to participate in any equity-based
incentive compensation plan or program adopted by the Company. Dr. Lough, if terminated while not in material breach of the Lough
Agreement, shall also have the right to participation payments paid to the Company (or any affiliate) from commercial transactions
associated with U.S. Patent Application No. 14/954,335 and PCT International Patent Application No. PCT/US2015/063114 and any
and all patents and patent applications, whether domestic or foreign, claiming priority thereto or arising therefrom (including
all divisionals, continuations, reissues, reexaminations, renewals, extensions, and supplementary protection certificates of any
such patents and patent application) and intellectual property rights associated with the patents (sales or licenses to third
parties).
The
terms of the Lough Agreement supersede any prior employment agreement or arrangement between Dr. Lough and the Company.
Dr.
Swanson
On
November 10, 2017, the Company entered into a new executive employment agreement (the “Swanson Agreement”) with Dr.
Swanson, effective as of the Effective Date, providing for the continuation of his role as the Chief Operating Officer and Chief
Translational Medicine Officer of the Company for a term of two years, which term shall be shall be automatically renewed for
successive one year periods thereafter unless either party provides the other party with written notice of his or its intention
not to renew the Swanson Agreement at least three months prior to the expiration of the initial term.
Pursuant
to the Swanson Agreement and in consideration for his services to the Company, Dr. Swanson received a $100,000 continuation bonus
and will receive a base salary of $400,000 per annum in accordance with the Company’s regular payroll practices. For each
fiscal year during the term of employment, Dr. Swanson shall be eligible to receive a bonus in the amount of 100% of annual salary,
if any, as may be determined from time to time by the Board in its discretion and shall be eligible to participate in any equity-based
incentive compensation plan or program adopted by the Company.
The
terms of the Swanson Agreement supersede any prior employment agreement or arrangement between Dr. Swanson and the Company.
Mr.
Stetson
On
November 10, 2017, the Company entered into a new executive employment agreement (the “Stetson Agreement”) with Mr.
Stetson, effective as of the Effective Date, providing for the continuation of his role as the Chief Financial Officer of the
Company for a term of two years, which term shall be shall be automatically renewed for successive one year periods thereafter
unless either party provides the other party with written notice of his or its intention not to renew the Stetson Agreement at
least three months prior to the expiration of the initial term.
Pursuant
to the Stetson Agreement and in consideration for his services to the Company, Mr. Stetson received a continuation bonus of 7,500
shares of restricted Common Stock which shall vest immediately upon the Effective Date and will receive a base salary of $168,000
per annum in accordance with the Company’s regular payroll practices. For each fiscal year during the term of employment,
Mr. Stetson shall be eligible to receive a bonus in the amount of 100% of annual salary, if any, as may be determined from time
to time by the Board in its discretion and shall be eligible to participate in any equity-based incentive compensation plan or
program adopted by the Company.
The
terms of the Stetson Agreement supersede any prior employment agreement or arrangement between Mr. Stetson and the Company.
Mr.
Hoyler
On
November 10, 2017, the Company entered into a new executive employment agreement (the “Hoyler Agreement”) with Mr.
Hoyler, effective as of the Effective Date, providing for the continuation of his role as General Counsel and appointment to the
role of Chief Legal Officer of the Company for a term of two years, which term shall be shall be automatically renewed for successive
one year periods thereafter unless either party provides the other party with written notice of his or its intention not to renew
the Hoyler Agreement at least three months prior to the expiration of the initial term.
Pursuant
to the Hoyler Agreement and in consideration for his services to the Company, Mr. Hoyler received a $50,000 continuation bonus
and will receive a base salary of $385,000 per annum in accordance with the Company’s regular payroll practices. For each
fiscal year during the term of employment, Mr. Hoyler shall be eligible to receive a bonus in the amount of 100% of annual salary,
if any, as may be determined from time to time by the Board in its discretion and shall be eligible to participate in any equity-based
incentive compensation plan or program adopted by the Company.
The
terms of the Hoyler Agreement supersede any prior employment agreement or arrangement between Mr. Hoyler and the Company.
The
foregoing descriptions of the Lough Agreement, Swanson Agreement, Stetson Agreement and Hoyler Agreement included herein do not
purport to be complete and are qualified in their entirety by reference to the complete text of the Lough Agreement, Swanson Agreement,
Stetson Agreement and Hoyler Agreement filed as Exhibit 10.1, Exhibit 10.2, Exhibit 10.3 and Exhibit 10.4, respectively, to this
Current Report on Form 8-K.